Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Compare

6,478 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VRTX Analyst Ratings

Moderate Buy

15 Buy

6 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Vertex

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VRTX Stock 12 Month Forecast

Average Price Target

$493.93

▲(14.03% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $493.93 with a high forecast of $575.00 and a low forecast of $414.00. The average price target represents a 14.03% change from the last price of $433.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"400":"$400","444":"$444","488":"$488","532":"$532","576":"$576"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":575,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$575.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":493.93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$493.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":414,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$414.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[400,444,488,532,576],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,425.57,437.06461538461537,448.55923076923074,460.05384615384617,471.54846153846154,483.0430769230769,494.5376923076923,506.03230769230765,517.526923076923,529.0215384615385,540.5161538461539,552.0107692307693,563.5053846153846,{"y":575,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,425.57,430.8284615384615,436.0869230769231,441.3453846153846,446.6038461538462,451.8623076923077,457.1207692307692,462.3792307692308,467.6376923076923,472.8961538461539,478.1546153846154,483.4130769230769,488.6715384615385,{"y":493.93,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,425.57,424.68,423.79,422.9,422.01,421.12,420.23,419.34,418.45,417.56,416.67,415.78,414.89,{"y":414,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":471.12,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":465.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":461.68,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":479.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":484.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":452.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":462.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":404.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$575.00

Average Price Target$493.93

Lowest Price Target$414.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Terence Flynn

Morgan Stanley

$438→$516

Buy

19.13%

Upside

Upgraded

12/03/25

Vertex Pharmaceuticals: Strategic Diversification and Promising Pipeline Justify Buy Rating

Louise Chen

Scotiabank

$495

Buy

14.28%

Upside

Reiterated

11/25/25

Scotiabank Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Cory Kasimov

Evercore ISI

$475

Buy

9.66%

Upside

Reiterated

11/12/25

Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Naz Rahman

Maxim Group

―

Hold

―

Reiterated

11/11/25

Maxim Group Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Joseph Stringer

Needham

―

Hold

―

Reiterated

11/10/25

Cautious Optimism: Hold Rating on Vertex Pharmaceuticals Amid Promising Clinical Trial DataWe found the data quite impressive, especially the significant 64% decrease in UPCR and the stabilization of eGFR, which increased by 3.3 mL/min/1.73 m² at IgAN patients. We came away more positive about the pove program and its potential in IgAN/pMN. We are Hold-rated on VRTX shares, but we believe the readouts from the developing mid- & late-stage kidney disease pipeline (IgAN, pMN, AMKD, ADPKD) could be value drivers for the stock. Disclaimers JOSEPH STRINGER, PH.D.

Andrew Fein

H.C. Wainwright

$478

Buy

10.35%

Upside

Reiterated

11/10/25

Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic DevelopmentValuation and Risks. Our price target of $478 is based on an equally weighted composite of: (a) $401/share, as a 15x multiple of taxed and diluted FY25 GAAP EPS of $42 discounted back to and (b) an NPV of $556/share (discount rate 8%, terminal growth rate of 1%). Risks to our investment thesis and target price include: (1) the failure of in further combination clinical studies; (2) the failure of to achieve our peak sales revenue; and (3) product competition.

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/10/25

Analysts' Top Healthcare Picks: Dyadic International (DYAI), REPRO-MED Systems (KRMD)

Myles Minter

William Blair

―

Buy

―

Reiterated

11/10/25

Vertex Pharmaceuticals' Promising Renal Franchise Developments Justify Buy RatingWe provide additional thoughts on IgAN updates at ASN in the full note.

Geoff Meacham

Citi

$575

Buy

32.75%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Climb Bio (NASDAQ: CLYM) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Gena Wang

Barclays

$414

Hold

-4.42%

Downside

Reiterated

11/10/25

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Paul Matteis

Stifel Nicolaus

―

Hold

―

Reiterated

11/09/25

Vertex Pharmaceuticals: Promising Data Amidst Competitive Renal Landscape and Investment Complexities

Phil Nadeau

TD Cowen

$525

Buy

21.21%

Upside

Reiterated

11/09/25

David Dai

UBS

$553→$546

Buy

26.05%

Upside

Reiterated

11/07/25

Vertex Pharmaceuticals: Strong Revenue Performance and Promising Prospects Justify Buy Rating

Brian Abrahams

RBC Capital

$423→$415

Hold

-4.19%

Downside

Reiterated

11/04/25

Vertex Pharmaceuticals price target lowered to $415 from $423 at RBC CapitalVertex Pharmaceuticals price target lowered to $415 from $423 at RBC Capital

Tazeen Ahmad

Bank of America Securities

―

Buy

―

Reiterated

11/04/25

Bank of America Securities Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Terence Flynn

Morgan Stanley

$438→$516

Buy

19.13%

Upside

Upgraded

12/03/25

Vertex Pharmaceuticals: Strategic Diversification and Promising Pipeline Justify Buy Rating

Louise Chen

Scotiabank

$495

Buy

14.28%

Upside

Reiterated

11/25/25

Scotiabank Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Cory Kasimov

Evercore ISI

$475

Buy

9.66%

Upside

Reiterated

11/12/25

Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Naz Rahman

Maxim Group

―

Hold

―

Reiterated

11/11/25

Maxim Group Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Joseph Stringer

Needham

―

Hold

―

Reiterated

11/10/25

Andrew Fein

H.C. Wainwright

$478

Buy

10.35%

Upside

Reiterated

11/10/25

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/10/25

Analysts' Top Healthcare Picks: Dyadic International (DYAI), REPRO-MED Systems (KRMD)

Myles Minter

William Blair

―

Buy

―

Reiterated

11/10/25

Vertex Pharmaceuticals' Promising Renal Franchise Developments Justify Buy RatingWe provide additional thoughts on IgAN updates at ASN in the full note.

Geoff Meacham

Citi

$575

Buy

32.75%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Climb Bio (NASDAQ: CLYM) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Gena Wang

Barclays

$414

Hold

-4.42%

Downside

Reiterated

11/10/25

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Paul Matteis

Stifel Nicolaus

―

Hold

―

Reiterated

11/09/25

Vertex Pharmaceuticals: Promising Data Amidst Competitive Renal Landscape and Investment Complexities

Phil Nadeau

TD Cowen

$525

Buy

21.21%

Upside

Reiterated

11/09/25

David Dai

UBS

$553→$546

Buy

26.05%

Upside

Reiterated

11/07/25

Vertex Pharmaceuticals: Strong Revenue Performance and Promising Prospects Justify Buy Rating

Brian Abrahams

RBC Capital

$423→$415

Hold

-4.19%

Downside

Reiterated

11/04/25

Vertex Pharmaceuticals price target lowered to $415 from $423 at RBC CapitalVertex Pharmaceuticals price target lowered to $415 from $423 at RBC Capital

Tazeen Ahmad

Bank of America Securities

―

Buy

―

Reiterated

11/04/25

Bank of America Securities Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

1 Month

xxx

Success Rate

15/19 ratings generated profit

Average Return

+2.68%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 78.95% of your transactions generating a profit, with an average return of +2.68% per trade.

3 Months

xxx

Success Rate

20/28 ratings generated profit

Average Return

+6.83%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +6.83% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

24/32 ratings generated profit

Average Return

+14.59%

reiterated a buy rating 22 days ago

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +14.59% per trade.

2 Years

xxx

Success Rate

27/31 ratings generated profit

Average Return

+25.52%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.10% of your transactions generating a profit, with an average return of +25.52% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRTX Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VRTX has received 39 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. VRTX average Analyst price target in the past 3 months is 493.93.

Each month's total comprises the sum of three months' worth of ratings.

VRTX Financial Forecast

VRTX Earnings Forecast

Next quarter’s earnings estimate for VRTX is $5.12 with a range of $4.46 to $5.78. The previous quarter’s EPS was $4.80. VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Sales Forecast

Next quarter’s sales forecast for VRTX is $3.19B with a range of $3.10B to $3.35B. The previous quarter’s sales results were $3.12B. VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Stock Forecast FAQ

What is VRTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 493.93.

What is VRTX’s upside potential, based on the analysts’ average price target?

Vertex Pharmaceuticals has 14.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VRTX a Buy, Sell or Hold?

Vertex Pharmaceuticals has a consensus rating of Moderate Buy which is based on 15 buy ratings, 6 hold ratings and 0 sell ratings.

What is Vertex Pharmaceuticals’s price target?

The average price target for Vertex Pharmaceuticals is 493.93. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $575.00 ,the lowest forecast is $414.00. The average price target represents 14.03% Increase from the current price of $433.15.

What do analysts say about Vertex Pharmaceuticals?

Vertex Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of VRTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

VRTX Analyst Ratings

VRTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vertex Pharmaceuticals

VRTX Analyst Recommendation Trends

VRTX Financial Forecast

VRTX Earnings Forecast

VRTX Sales Forecast

VRTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts